Company Information

VISTA PHARMACEUTICALS LTD.

NSE : NABSE : 524711ISIN CODE : INE427C01021Industry : Pharmaceuticals & DrugsHouse : Private
BSE10.80-0.04 (-0.37 %)
PREV CLOSE ( ) 10.84
OPEN PRICE ( ) 10.33
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1559
TODAY'S LOW / HIGH ( )10.33 10.85
52 WK LOW / HIGH ( ) 9.116.59
NSE
This Company is not listed in NSE
ChairmanDhananjaya Alli
Managing DirectorMurali Meraga
Company SecretaryBarkha Jain
Non Executive DirectorStanley Prabhakar Reddy
Umakanth Katta
Divakar Reddy Yerrabommanahalli
Mallem Hanumantha Rao
Non Executive Independent DirectorUmesh V Banakar
Divya Bhavani Chakravarthula
Rama Mohan Manamasa
Naga Raja Madineni
Madhu Sudan Anchi
Swapna Priya Gunduboina
Anumala Ravi Chandra kumar
Whole Time DirectorPavan Sathvik Gilaka
Incorporation Year : 25-01 1991

Registered Office :

Address : Plot Nos. 10 To 14 And 16 To 20, T S I I C Industrial Estate,Chityal, Gopalaipalli Village,Narketpally Mandal Nalgonda Dist,
Telangana-508254 .

Phone : 08682 272552 / 09291015956

Industry : Pharmaceuticals & Drugs

Listing : BSE

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.